Real-World study asks: does this skin disease treatment improve lives?
NCT ID NCT06785675
Summary
This study aims to understand how a medication called secukinumab affects the daily lives and satisfaction of people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Researchers will follow 60 patients in the United Arab Emirates for 24 weeks, collecting information from their medical records and asking them to complete questionnaires about their treatment experience and quality of life. The goal is to gather real-world data on whether this treatment helps patients feel better and more satisfied with their care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGAl Ain Abu Dhabi, United Arab Emirates, United Arab Emirates
-
Novartis Investigative Site
RECRUITINGAbu Dhabi, United Arab Emirates
-
Novartis Investigative Site
RECRUITINGRas al-Khaimah, United Arab Emirates
-
Novartis Investigative Site
RECRUITINGSharjah city, United Arab Emirates
Conditions
Explore the condition pages connected to this study.